Figure 1.

Two‐prong inhibitory strategy to suppress SARS‐CoV‐2 replication and clinical manifestation of COVID‐19. (A) Delivery of siRNA cocktail targeting multiple genes of SARS‐CoV‐2 to inhibit further generation of viral particles, and (B) Intravenous administration of complement inhibitor to alleviate the generation of IL‐6 and other proinflammatory cytokines, thereby attenuating the induction of cytokine storm: an attribute to COVID‐19. COVID‐19, coronavirus disease 2019; E, envelope protein; ER, endoplasmic reticulum; IL‐6, interleukin 6; N, nucleocapsid; Nsp, non structural protein; S, spike protein; SARS‐CoV‐2, severe acute respiratory syndrome coronavirus 2; siRNA, small interfering RNA